**AMGEN INC** Form 4 May 11, 2015

## FORM 4

#### **OMB APPROVAL**

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

if no longer subject to Section 16. Form 4 or

Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

January 31, Expires: 2005 Estimated average

Form 5 obligations may continue.

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

burden hours per response... 0.5

See Instruction

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person \* Balachandran Madhavan

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

AMGEN INC [AMGN]

(Check all applicable)

(Middle)

3. Date of Earliest Transaction

Director

10% Owner \_ Other (specify

ONE AMGEN CENTER DRIVE

(First)

(Street)

(Month/Day/Year)

X\_ Officer (give title below)

05/07/2015

EVP, Operations

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check Applicable Line)

Filed(Month/Day/Year)

\_X\_ Form filed by One Reporting Person

Form filed by More than One Reporting

Person

**THOUSAND** OAKS, CA 91320-1799

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit orDisposed (Instr. 3, 4	of (D)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	05/07/2015		M	6,000	A	\$ 58.43	39,394	D		
Common Stock	05/07/2015		M	15,750	A	\$ 54.69	55,144	D		
Common Stock	05/07/2015		S	6,000	D	\$ 157.9153 (1)	49,144	D		
Common Stock	05/07/2015		S	15,750	D	\$ 157.8542 (2)	33,394 (3) (4)	D		

### Edgar Filing: AMGEN INC - Form 4

Common Stock 56,573 I Family Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nqso (Right to Buy)	\$ 58.43	05/07/2015		M		6,000	04/26/2011	04/26/2020	Common Stock	6,000
Nqso (Right to Buy)	\$ 54.69	05/07/2015		M		15,750	04/25/2013	04/25/2021	Common Stock	15,750

# **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Balachandran Madhavan ONE AMGEN CENTER DRIVE THOUSAND OAKS, CA 91320-1799

EVP, Operations

## **Signatures**

/s/ Madhavan Balachandran 05/07/2015

\*\*Signature of Reporting Date
Person

Reporting Owners 2

Edgar Filing: AMGEN INC - Form 4

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported is an average price. The prices ranged from \$157.90 to \$157.94 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.
- The price reported is an average price. The prices ranged from \$157.81 to \$157.93 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.
  - These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 855 RSUs which vest on 4/27/2016; 17,845 RSUs which vest in one installment of 8,789 on 7/31/2015 and one installment of 9,056 on 7/31/2016; 5,010 RSUs
- which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 4,707 RSUs which vest in two equal installments of 1,553 each on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018; and 3,677 RSUs which vest in two equal installments of 1,213 on 1/30/2017 and 1/30/2018 and one installment of 1,251 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- These shares include 1,300 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity

  Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.